• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于化学功能通过催化剂和相生成选择性κ-阿片受体激动剂的药效团

Chemical function-based pharmacophore generation of selective kappa-opioid receptor agonists by catalyst and phase.

作者信息

Zhang Jing, Liu Guixia, Tang Yun

机构信息

Laboratory of Molecular Modeling and Design, School of Pharmacy, East China University of Science and Technology, Box 268, 130 Meilong Road, Shanghai, 200237, China.

出版信息

J Mol Model. 2009 Sep;15(9):1027-41. doi: 10.1007/s00894-008-0418-5. Epub 2009 Feb 11.

DOI:10.1007/s00894-008-0418-5
PMID:19205759
Abstract

Two chemical function-based pharmacophore models of selective kappa-opioid receptor agonists were generated by using two different programs: Catalyst/HypoGen and Phase. The best output hypothesis (Hypo1) of HypoGen consisted of five features: one hydrogen-bond acceptor (HA), three hydrophobic points (HY), and one positive ionizable function (PI). The highest scoring model (Hypo2) produced by Phase comprised four features: one acceptor (A), one positive ionizable function (P), and two aromatic ring features (R). These two models (Hypo1 and Hypo2) were then validated by test set prediction and enrichment factors. They were shown to be able to identify highly potent kappa-agonists within a certain range, and satisfactory enrichments were achieved. The features of these two pharmacophore models were similar and consistent with experiment data. The models produced here were also generally in accord with other reported models. Therefore, our pharmacophore models were considered as valuable tools for 3D virtual screening, and could be useful for designing novel kappa-agonists.

摘要

利用两种不同程序Catalyst/HypoGen和Phase生成了选择性κ-阿片受体激动剂的两种基于化学功能的药效团模型。HypoGen的最佳输出假设(Hypo1)由五个特征组成:一个氢键受体(HA)、三个疏水点(HY)和一个正可电离功能(PI)。Phase产生的得分最高的模型(Hypo2)包含四个特征:一个受体(A)、一个正可电离功能(P)和两个芳香环特征(R)。然后通过测试集预测和富集因子对这两个模型(Hypo1和Hypo2)进行验证。结果表明,它们能够在一定范围内识别高效κ-激动剂,并获得了令人满意的富集效果。这两种药效团模型的特征相似且与实验数据一致。这里产生的模型也总体上与其他报道的模型一致。因此,我们的药效团模型被认为是用于三维虚拟筛选的有价值工具,并且可能有助于设计新型κ-激动剂。

相似文献

1
Chemical function-based pharmacophore generation of selective kappa-opioid receptor agonists by catalyst and phase.基于化学功能通过催化剂和相生成选择性κ-阿片受体激动剂的药效团
J Mol Model. 2009 Sep;15(9):1027-41. doi: 10.1007/s00894-008-0418-5. Epub 2009 Feb 11.
2
Chemical function-based pharmacophore development for novel, selective kappa opioid receptor agonists.基于化学功能的新型选择性κ阿片受体激动剂药效团开发
J Mol Graph Model. 2008 Sep;27(2):131-9. doi: 10.1016/j.jmgm.2008.03.007. Epub 2008 Mar 28.
3
Modeling of kappa-opioid receptor/agonists interactions using pharmacophore-based and docking simulations.使用基于药效团和对接模拟的方法对κ-阿片受体/激动剂相互作用进行建模。
J Med Chem. 2000 Jun 1;43(11):2124-34. doi: 10.1021/jm991161k.
4
Molecular modeling on kappa opioid receptor and its interaction with nonpeptide kappa opioid agonists.κ阿片受体的分子建模及其与非肽类κ阿片激动剂的相互作用
Zhongguo Yao Li Xue Bao. 1999 Feb;20(2):131-6.
5
Behavioral Pharmacology of Novel Kappa Opioid Receptor Antagonists in Rats.新型κ阿片受体拮抗剂在大鼠体内的行为药理学研究。
Int J Neuropsychopharmacol. 2019 Nov 1;22(11):735-745. doi: 10.1093/ijnp/pyz054.
6
Conformationally restricted κ-opioid receptor agonists: Synthesis and pharmacological evaluation of diastereoisomeric and enantiomeric decahydroquinoxalines.构象受限的κ-阿片受体激动剂:非对映异构体和对映体十氢喹喔啉的合成及药理学评价
Bioorg Med Chem Lett. 2015 Nov 15;25(22):5326-30. doi: 10.1016/j.bmcl.2015.09.040. Epub 2015 Sep 16.
7
Kappa opioid antagonist effects of the novel kappa antagonist 5'-guanidinonaltrindole (GNTI) in an assay of schedule-controlled behavior in rhesus monkeys.新型κ阿片受体拮抗剂5'-胍基纳曲吲哚(GNTI)在恒河猴程序控制行为试验中的κ阿片受体拮抗剂作用。
Psychopharmacology (Berl). 2002 Oct;163(3-4):412-9. doi: 10.1007/s00213-002-1038-x. Epub 2002 Mar 13.
8
Schild (apparent pA2) analysis of a kappa-opioid antagonist in Planaria.涡虫中κ-阿片受体拮抗剂的希尔德(表观pA2)分析。
Eur J Pharmacol. 2006 Jul 1;540(1-3):200-1. doi: 10.1016/j.ejphar.2006.04.027. Epub 2006 May 3.
9
Diazabicyclononanones, a potent class of kappa opioid analgesics.
Farmaco. 2002 Jul;57(7):531-4. doi: 10.1016/s0014-827x(02)01243-0.
10
The effect of kappa-opioid receptor agonists on tetrodotoxin-resistant sodium channels in primary sensory neurons.κ-阿片受体激动剂对初级感觉神经元中河豚毒素抗性钠通道的影响。
Anesth Analg. 2009 Aug;109(2):632-40. doi: 10.1213/ane.0b013e3181a909a4.

引用本文的文献

1
The Use of Computational Approaches in the Discovery and Mechanism Study of Opioid Analgesics.计算方法在阿片类镇痛药发现及作用机制研究中的应用
Front Chem. 2020 May 15;8:335. doi: 10.3389/fchem.2020.00335. eCollection 2020.

本文引用的文献

1
Chemical function-based pharmacophore development for novel, selective kappa opioid receptor agonists.基于化学功能的新型选择性κ阿片受体激动剂药效团开发
J Mol Graph Model. 2008 Sep;27(2):131-9. doi: 10.1016/j.jmgm.2008.03.007. Epub 2008 Mar 28.
2
Novel malonamide derivatives as potent kappa opioid receptor agonists.
Bioorg Med Chem Lett. 2007 Apr 1;17(7):1951-5. doi: 10.1016/j.bmcl.2007.01.053. Epub 2007 Jan 25.
3
PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results.PHASE:药效团识别、3D QSAR模型开发及3D数据库筛选的新引擎:1. 方法与初步结果
J Comput Aided Mol Des. 2006 Oct-Nov;20(10-11):647-71. doi: 10.1007/s10822-006-9087-6. Epub 2006 Nov 24.
4
GALAHAD: 1. pharmacophore identification by hypermolecular alignment of ligands in 3D.加拉哈德:1. 通过三维配体的超分子比对进行药效团识别。
J Comput Aided Mol Des. 2006 Sep;20(9):567-87. doi: 10.1007/s10822-006-9082-y. Epub 2006 Oct 19.
5
A combined ligand-based and target-based drug design approach for G-protein coupled receptors: application to salvinorin A, a selective kappa opioid receptor agonist.一种用于G蛋白偶联受体的基于配体和基于靶点的联合药物设计方法:应用于选择性κ阿片受体激动剂Salvinorin A。
J Comput Aided Mol Des. 2006 Jul-Aug;20(7-8):471-93. doi: 10.1007/s10822-006-9067-x. Epub 2006 Sep 29.
6
Novel phenylamino acetamide derivatives as potent and selective kappa opioid receptor agonists.
Bioorg Med Chem Lett. 2006 Feb;16(3):645-8. doi: 10.1016/j.bmcl.2005.10.034. Epub 2005 Nov 2.
7
Potent and highly selective kappa opioid receptor agonists incorporating chroman- and 2,3-dihydrobenzofuran-based constraints.包含基于色满和2,3-二氢苯并呋喃结构的强效且高选择性κ阿片受体激动剂。
Bioorg Med Chem Lett. 2005 Dec 1;15(23):5114-9. doi: 10.1016/j.bmcl.2005.08.094. Epub 2005 Oct 3.
8
Arylacetamide kappa opioid receptor agonists with reduced cytochrome P450 2D6 inhibitory activity.
Bioorg Med Chem Lett. 2005 May 16;15(10):2647-52. doi: 10.1016/j.bmcl.2005.03.020.
9
Synthesis and evaluation of novel peripherally restricted kappa-opioid receptor agonists.新型外周限制性κ-阿片受体激动剂的合成与评价
Bioorg Med Chem Lett. 2005 Feb 15;15(4):1091-5. doi: 10.1016/j.bmcl.2004.12.018.
10
Azepinone as a conformational constraint in the design of kappa-opioid receptor agonists.氮杂环庚酮作为κ-阿片受体激动剂设计中的构象限制因素。
Bioorg Med Chem Lett. 2004 Nov 15;14(22):5693-7. doi: 10.1016/j.bmcl.2004.08.041.